Doloromics appoints Chief Research and Development Officer

"I’m both thrilled and privileged to commit the full measure of my expertise and passion in executing the core mission of Doloromics"

Doloromics has announced the appointment of Dr Chris Flores as President and Chief Research and Development Officer. In this role, Flores will be responsible for leading the company’s portfolio of drug discovery and development programs, two of which are scheduled to launch in early 2022, while building relationships with strategic partners and collaborators to support these efforts.

"After an extensive and diverse experience in the Pharmaceutical and Consumer sectors of Johnson & Johnson, I’m both thrilled and privileged to commit the full measure of my expertise and passion in executing the core mission of Doloromics, to eradicate pain in patients who remain tragically underserved by current standards of care," said Chris Flores, PhD.

Flores will join the leadership team following a 19-year career at Johnson & Johnson, where he held several executive positions, including VP of Neuroscience, La Jolla R&D Site Head, Pain Franchise Strategy Leader, Head of Pain Discovery and Global External Innovation Head of Discovery Sciences within Janssen Research & Development as well as Head of Emerging Science and Innovation Strategy for J&J Consumer Companies.

Companies